Open Interest and Volume Dynamics
The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives rose sharply by 4,894 contracts, a 14.88% increase from the previous figure of 32,894 to 37,788. This surge in OI is accompanied by a robust trading volume of 57,580 contracts, indicating heightened trader interest and active positioning in the stock’s futures and options.
In monetary terms, the futures segment alone accounted for a value of approximately ₹33,075 lakhs, while the options segment’s value was substantially higher at ₹30,305.71 crores, culminating in a total derivatives value of ₹38,721.78 lakhs. This substantial derivatives activity underscores the growing focus on Mankind Pharma within the Pharmaceuticals & Biotechnology sector.
Price Performance and Technical Indicators
On 20 May 2026, Mankind Pharma’s stock price demonstrated resilience by gaining 3.02% intraday, touching a high of ₹2,573.8. This performance outpaced the sector’s 0.42% gain and contrasted with the Sensex’s decline of 0.46%, highlighting the stock’s relative strength. Notably, the stock reversed a two-day losing streak, signalling a potential trend reversal.
Technically, Mankind Pharma is trading above its key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — which collectively indicate a bullish momentum. However, delivery volumes have declined by 21.47% compared to the five-day average, suggesting that while speculative activity is rising, long-term investor participation has moderated.
Market Capitalisation and Mojo Score Upgrade
With a market capitalisation of ₹1,02,278 crores, Mankind Pharma is classified as a mid-cap stock. The company’s Mojo Score has improved to 65.0, reflecting a Hold rating, upgraded from Sell on 8 May 2026. This upgrade reflects the stock’s improved fundamentals and technical outlook, supported by the recent surge in derivatives activity and price strength.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Interpreting the Open Interest Surge: Market Positioning and Directional Bets
The 14.88% increase in open interest, coupled with strong volume, suggests that market participants are actively building positions in anticipation of further price movement. The rise in OI typically indicates fresh money entering the market rather than existing positions being squared off, which often precedes a sustained trend.
Given the stock’s recent outperformance relative to its sector and the Sensex, the derivatives activity likely reflects bullish sentiment. Traders may be positioning for continued upside, supported by the stock’s technical strength and improving fundamentals. The futures value of ₹33,075 lakhs and the massive options value exceeding ₹30,000 crores highlight significant hedging and speculative interest.
However, the decline in delivery volumes signals a cautious stance among long-term investors, possibly awaiting confirmation of the trend before committing capital. This divergence between speculative and delivery volumes is a key factor for investors to monitor, as it may indicate short-term volatility or consolidation before a decisive move.
Sectoral Context and Comparative Performance
Mankind Pharma operates within the Pharmaceuticals & Biotechnology sector, which has seen moderate gains recently. The stock’s 2.82% one-day return on 20 May 2026 notably outperformed the sector’s 0.42% gain and the broader Sensex’s 0.46% decline. This relative strength positions Mankind Pharma as a leading mid-cap player within its industry.
Investors should consider this outperformance in the context of the company’s upgraded Mojo Grade to Hold, reflecting a more balanced risk-reward profile. While the stock shows promise, the Hold rating suggests that investors should weigh potential gains against sectoral headwinds and market volatility.
Is Mankind Pharma Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Investor Takeaways and Outlook
The recent surge in open interest and volume in Mankind Pharma’s derivatives market signals increased market attention and potential for directional moves. The stock’s technical positioning above all major moving averages and its outperformance relative to sector and benchmark indices support a cautiously optimistic outlook.
Investors should remain vigilant of the declining delivery volumes, which may temper enthusiasm among long-term holders. The Hold Mojo Grade reflects this balanced view, suggesting that while the stock has upside potential, it also carries risks that warrant careful monitoring.
Given the mid-cap status and ₹1,02,278 crore market capitalisation, Mankind Pharma remains a significant player in the Pharmaceuticals & Biotechnology sector. The derivatives market activity provides valuable insight into trader sentiment and possible future price trajectories, making it an important factor for portfolio consideration.
Overall, the combination of improved fundamentals, technical strength, and heightened derivatives interest positions Mankind Pharma as a stock to watch closely in the coming weeks.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
